WO1997026321A3 - Recombinant expression of proteins from secretory cell lines - Google Patents

Recombinant expression of proteins from secretory cell lines Download PDF

Info

Publication number
WO1997026321A3
WO1997026321A3 PCT/US1997/000761 US9700761W WO9726321A3 WO 1997026321 A3 WO1997026321 A3 WO 1997026321A3 US 9700761 W US9700761 W US 9700761W WO 9726321 A3 WO9726321 A3 WO 9726321A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cell lines
proteins
recombinant expression
secretory cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/000761
Other languages
French (fr)
Other versions
WO1997026321A2 (en
Inventor
Christopher B Newgard
Philippe A Halban
Karl D Normington
Samuel A Clark
Anice E Thigpen
Christian Quaade
Fred Kruse
Dennis Mcgarry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagene Inc
The University of Texas System
The University of Texas at Austin
Original Assignee
Betagene Inc
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/589,028 external-priority patent/US6087129A/en
Application filed by Betagene Inc, The University of Texas System, The University of Texas at Austin filed Critical Betagene Inc
Priority to AU17505/97A priority Critical patent/AU718254B2/en
Priority to EP97904802A priority patent/EP0910578A2/en
Publication of WO1997026321A2 publication Critical patent/WO1997026321A2/en
Publication of WO1997026321A3 publication Critical patent/WO1997026321A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines, and methods for isolating novel amylin receptors.
PCT/US1997/000761 1996-01-19 1997-01-17 Recombinant expression of proteins from secretory cell lines Ceased WO1997026321A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU17505/97A AU718254B2 (en) 1996-01-19 1997-01-17 Recombinant expression of proteins from secretory cell lines
EP97904802A EP0910578A2 (en) 1996-01-19 1997-01-17 Recombinant expression of proteins from secretory cell lines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/589,028 US6087129A (en) 1996-01-19 1996-01-19 Recombinant expression of proteins from secretory cell lines
US08/589,028 1996-01-19
US2842796P 1996-10-15 1996-10-15
US60/028,427 1996-10-15

Publications (2)

Publication Number Publication Date
WO1997026321A2 WO1997026321A2 (en) 1997-07-24
WO1997026321A3 true WO1997026321A3 (en) 1998-01-08

Family

ID=26703682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000761 Ceased WO1997026321A2 (en) 1996-01-19 1997-01-17 Recombinant expression of proteins from secretory cell lines

Country Status (4)

Country Link
EP (1) EP0910578A2 (en)
AU (1) AU718254B2 (en)
CA (1) CA2246431A1 (en)
WO (1) WO1997026321A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU2455199A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
AU2219999A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Methods for preparing and using immortalized human neuroendocrine cells
US6322962B1 (en) 1998-08-14 2001-11-27 Board Of Regents, The University Of Texas System Sterol-regulated Site-1 protease and assays of modulators thereof
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CN102816241B (en) 2004-02-09 2015-07-22 人类基因科学公司 Albumin fusion proteins
KR20140011431A (en) * 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. Hybrid polypeptides with selectable properties
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc PANCREAS POLYPEPTIDE FAMILY MOTIVES AND POLYPEPTIDES CONTAINING THEM
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
MX2008002028A (en) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties.
EP1957527A2 (en) * 2005-11-03 2008-08-20 Liat Mintz Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP3255149A3 (en) * 2006-05-02 2018-04-18 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
WO2010080494A1 (en) * 2008-12-19 2010-07-15 Tercica, Inc. Methods for identifying degradation products in a polypeptide sample
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
ES2759007T3 (en) 2010-03-04 2020-05-07 Ventana Med Syst Inc Processing system to process samples using acoustic energy
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9341639B2 (en) 2013-07-26 2016-05-17 Industrial Technology Research Institute Apparatus for microfluid detection
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
JP6989262B2 (en) 2014-10-27 2022-01-05 アセコー インコーポレイテッド Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289287A2 (en) * 1987-04-27 1988-11-02 Amylin Pharmaceuticals, Inc. Amyloid peptides
EP0309100A2 (en) * 1987-08-26 1989-03-29 Amylin Pharmaceuticals, Inc. Use of amylin or CGRP for the treatment of diabetes mellitus
WO1993002697A1 (en) * 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289287A2 (en) * 1987-04-27 1988-11-02 Amylin Pharmaceuticals, Inc. Amyloid peptides
EP0309100A2 (en) * 1987-08-26 1989-03-29 Amylin Pharmaceuticals, Inc. Use of amylin or CGRP for the treatment of diabetes mellitus
WO1993002697A1 (en) * 1991-08-08 1993-02-18 Amylin Pharmaceuticals, Inc. Production of peptide amides
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
C.X. MOORE AND G.J.S. COOPER: "Co-secretion of maylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents", BIOCHEM. AND BIOPHYS. RES. COMMUNICATIONS, vol. 179, no. 1, 30 August 1991 (1991-08-30), ACADEMIC PRESS, NEW YORK, US, pages 1 - 9, XP002036171 *
FOX ET AL: "HUMAN ISLET AMYLOID POLYPEPTIDE TRANSGENIC MICE AS A MODEL OF NON-INSULIN-DEPENDENT DIABETES MELLITUS (NIDDM)", FEBS LETTERS, vol. 323, no. 1/02, 1 May 1993 (1993-05-01), pages 40 - 44, XP002009609 *
G.J.S. COOPER ET AL.: "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patient", PROC. NATL.ACAD SCI., vol. 84, December 1987 (1987-12-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 8628 - 8632, XP002036174 *
HOEPPENER J W M ET AL: "CHRONIC EOVERPRODUCTION OF ISLET AMYLOID POLYPEPTIDE/AMYLIN IN TRANSGENIC MICE: LYSOSOMAL LOCALIZATION OF HUMAN ISLET AMYLOID POLYPEPTIDE AND LACK OF MARKED HY}ERGLYCAEMIA OR HYPERINSULINAEMIA", DIABETOLOGIA, vol. 36, no. 12, 1 December 1993 (1993-12-01), pages 1258 - 1265, XP000576160 *
J.D. LEFFERT ET AL.: "Rat amylin: Cloning and tissue-specific expression in pancreatic islets", PROC. NATL.ACAD SCI., vol. 86, May 1989 (1989-05-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 3127 - 3130, XP002036172 *
O'BRIEN T D ET AL: "HUMAN ISLET AMYLOID POLYPEPTIDE EXPRESSION IN COS-1 CELLS A MODEL OF INTRACELLULAR AMYLOIDOGENESIS", AMERICAN JOURNAL OF PATHOLOGY, vol. 147, no. 3, 1 September 1995 (1995-09-01), pages 609 - 616, XP000590832 *
P. WESTERMARK ET AL.: "Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells", PROC. NATL.ACAD SCI., vol. 84, June 1987 (1987-06-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 3881 - 3885, XP002036173 *

Also Published As

Publication number Publication date
AU718254B2 (en) 2000-04-13
CA2246431A1 (en) 1997-07-24
AU1750597A (en) 1997-08-11
EP0910578A2 (en) 1999-04-28
WO1997026321A2 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
AU7599500A (en) Novel gl50 molecules and uses therefor
ZA200201512B (en) PD-1, a receptor for B7-4, and uses thereof.
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
AU4427389A (en) Peptides and antibodies that inhibit integrin-ligand binding
US6114148C1 (en) High level expression of proteins
EP0260148A3 (en) Improved recombinant expression method, vector and transformed cells
MX9709549A (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses.
EP1020528A3 (en) Method for producing secreted proteins
DE68929402D1 (en) METHOD FOR PRODUCING WATER-SOLUBLE POLYPEPTIDES
GR3026230T3 (en) Expression of recombinant polypeptides with improved purification
AUPN442295A0 (en) Regulated autocrine growth of mammalian cells
WO2001025438A3 (en) Ifn-alpha homologues
NZ508863A (en) Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU7057098A (en) Improved prokaryotic expression of protein
YU41798A (en) Scf analogous compositions and methods
WO1996014412A3 (en) cDNA ENCODING A BMP TYPE II RECEPTOR
AU2002320301A1 (en) Novel pgc-1 isoforms and uses therefor
FR2692282B1 (en) CLONING OF THE GENE ENCODING THE PROTEIN GP28.5 OF T. GONDII; PEPTIDE FRAGMENTS FROM SUCH PROTEIN AND THEIR APPLICATIONS.
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO2001040257A3 (en) Modified il-12 subunits and nucleic acids encoding them
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
EP1900816A3 (en) GL50 molecules and uses therefor
WO2000018890A3 (en) Protein phosphatase molecules and uses therefor
WO2000032746A3 (en) Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

ENP Entry into the national phase

Ref document number: 2246431

Country of ref document: CA

Ref country code: CA

Ref document number: 2246431

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997904802

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97526209

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997904802

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997904802

Country of ref document: EP